Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia
Bone Marrow Transplant
.
2018 Jun;53(6):795-799.
doi: 10.1038/s41409-018-0124-6.
Epub 2018 Mar 14.
Authors
Katie S Gatwood
1
,
Kathryn A Culos
2
,
Laura A Binari
3
,
Brian G Engelhardt
4
,
Adetola Kassim
4
,
Michael T Byrne
4
,
Stacey A Goodman
4
,
Wichai Chinratanalab
4
,
Salyka M Sengsayadeth
4
,
John P Greer
4
,
Madan Jagasia
4
,
Bipin N Savani
4
Affiliations
1
Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA. katie.s.gatwood@vanderbilt.edu.
2
Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.
3
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
4
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
PMID:
29540851
DOI:
10.1038/s41409-018-0124-6
No abstract available
Publication types
Letter
MeSH terms
Anemia, Aplastic / drug therapy
Anemia, Aplastic / therapy*
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Male
Rituximab / administration & dosage*
Transplantation Conditioning / methods*
Substances
Rituximab